TX-MARY-KAY
21.4.2022 19:05:08 CEST | Business Wire | Press release
Mary Kay Inc., a leading corporate advocate of women’s empowerment and entrepreneurship, announced today its second World Series of Innovation (WSI) Challenge in partnership with Network for Teaching Entrepreneurship (NFTE). The global educational experience invites young people ages 13-24 to channel their critical thinking and problem-solving skills to find solutions for the biggest challenges facing the world today and help advance the UN Sustainable Development Goals (SDGs) while fostering an entrepreneurial mindset.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220421005111/en/
Mary Kay’s World Series of Innovation Challenge encourages young people from around the world to submit innovative solutions to address Sustainable Development Goal 5: Gender Equality . Specifically, this challenge asked students to think about ways to promote workplace equality and ensure equal access to economic opportunity for women and girls. Pre-COVID, decades of data demonstrated the rise of women in the workforce. Even though the wage gap persisted, more women were joining the labor market every year. But pandemic job losses disproportionately impacted women, and since 2020, the uphill climb to workforce equality has grown even steeper.
“Congratulations to the winners of this year’s World Series of Innovation Challenge! Mary Kay knows the importance of entrepreneurship and the role it plays in the world today and in the future, which is why we invest annually in programs and initiatives to help empower women and girls around the world,” said Deborah Gibbins, Chief Operating Officer for Mary Kay Inc. “We are beyond excited for the competitors and winners who tackled this challenge and demonstrated solution-forward thinking and identified great opportunities to achieve gender equality in the workplace.”
NFTE is a global educational nonprofit focused on bringing the power of entrepreneurship to youth in low-income communities. The World Series of Innovation (WSI) Challenge invites corporate sponsored challenges to address the UN Sustainable Development Goals.
NFTE, which reaches 50,000+ youth worldwide, saw more than 3,000 students of diverse backgrounds submit ideas in this year’s WSI Challenges. More than 400 students participated in the Mary Kay-sponsored challenge. The three winners of Mary Kay’s 2021 Challenge are:
- First Place: STEMinists created an online portal that connects female professionals to young female STEM students as mentors to bolster female success in STEM fields. Developed by 15-year-old Misaki Nguyen of Silver Creek High School in San Jose, California.
- Second Place: Pads for Peace , a feminine product subscription box service, donates a box to homeless shelters for every box purchased. Developed by 14-year-olds Ashley Cohen, Olivia Mooney and Ashley Simonian of Brentwood School in Los Angeles.
- Third Place: Black Girls Mean Business , a virtual summer business program for Black high school girls, matches young professionals with mentors from industry leading businesses. Developed by 17-year-olds Brianna Holmes, Alyssa Torres, Rachel Holmes, and 18-year-old Cherry Zhang of Silver Creek High School in San Jose, California.
“Every year, teams of young people from across the world respond to the call of WSI by tapping into their creativity for innovative solutions to some of the world’s most pressing problems,” said Dr. J.D. LaRock, President and CEO of NFTE. "Young people are bold and ambitious and often motivated by what they’re passionate about. WSI offers them an opportunity to develop their ideas and rewards them for thinking creatively about issues such as poverty, equity and inclusion, and social and environmental justice.”
The 2021 NFTE World Series of Innovation is presented by Citi Foundation and features challenges from Bank of the West, Citi Foundation, Ernst & Young LLP (EY US), Mary Kay Inc., Maxar Technologies, PIMCO, and Saint-Gobain.
For more information about the World Series of Innovation and all challenges, visit https://innovation.nfte.com
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company nearly 60 years ago with three goals: to develop rewarding opportunities for women, offer irresistible products and make the world a better place. Over the years, her dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. In addition to investing in the science behind beauty and manufacturing cutting-edge products, Mary Kay is committed to empowering women and their families. By supporting cancer research, protecting domestic abuse survivors, beautifying communities and encouraging children to follow their dreams, our company ensures that Mary Kay Ash’s original vision continues to shine today. Learn more at MaryKayGlobal.com .
About NFTE
Network for Teaching Entrepreneurship (NFTE) is a global nonprofit organization that provides high-quality entrepreneurship education to middle and high school students from under-resourced communities, as well as programs for college students and adults. NFTE reaches 50,000+ students annually in 25 states across the U.S. and offers programs in 18 additional countries. We have educated more than a million students through in-school, out-of-school, college, and summer camp programs, offered in person and online. To learn more about how we are promoting inclusive capitalism and building the next generation of diverse entrepreneurs, visit www.nfte.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005111/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom